Zolpidem sublingual - Paratek Pharmaceuticals

Drug Profile

Zolpidem sublingual - Paratek Pharmaceuticals

Alternative Names: Intermezzo; Zolpidem hemitartrate; Zolpidem lozenge; Zolpidem tartrate; Zolpidem tartrate lozenge; Zolpidem tartrate sublingual; Zolpidem tartrate sublingual tablet; Zolpidem tartrate sublingual tablet C-IV

Latest Information Update: 01 Nov 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TransOral Pharmaceuticals
  • Developer Paratek Pharmaceuticals
  • Class Acetamides; Hypnosedatives; Imidazoles; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Insomnia

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 30 Oct 2014 Transcept Pharmaceuticals Inc merged into Paratek Pharmaceuticals and is now called Paratek Pharmaceuticals
  • 10 May 2012 Pharmacokinetics data from a clinical trial in healthy volunteers presented at the annual meeting of the American Psychiatric Association (APA-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top